Results 21 to 30 of about 53,199 (230)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure

EBioMedicine, 2015
The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib – exhibiting a low-nanomolar IC50 – suggesting
David S. Pitcher, Kate de Mattos-Shipley, Konstantinos Tzortzis, Holger W. Auner, Anastasios Karadimitris, Maurits F. Kleijnen   +5 more
doaj   +1 more source

Gabapentin Inhibits Bortezomib-Induced Mechanical Allodynia Through Supraspinal Action in Mice

Journal of Pharmacological Sciences, 2014
Bortezomib, an inhibitor of proteasome holoenzyme, is used to treat relapsed and refractory multiple myeloma. Peripheral neuropathy is a treatment-limiting adverse effect of bortezomib and is very difficult to control.
Ryo Kitamura, Tsugunobu Andoh, Shizuka Mizoguchi, Yukako Saito, Hiroki Takahata, Yasushi Kuraishi   +5 more
doaj   +1 more source

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.

PLoS ONE, 2013
BACH2, a B-cell specific transcription factor, plays a critical role in oxidative stress-mediated apoptosis. Bortezomib (Velcade(TM)) is widely used to treat relapsed mantle cell lymphoma (MCL) patients despite varying clinical outcomes.
Zheng Chen, Eric F Pittman, Jorge Romaguera, Luis Fayad, Michael Wang, Sattva S Neelapu, Peter McLaughlin, Larry Kwak, Nami McCarty   +8 more
doaj   +1 more source

Iron increases the susceptibility of multiple myeloma cells to bortezomib

Haematologica, 2013
Multiple myeloma is a malignant still incurable plasma cell disorder. Pharmacological treatment based on proteasome inhibition has improved patient outcome; however, bortezomib-resistance remains a major clinical problem.
Alessandro Campanella, Paolo Santambrogio, Francesca Fontana, Michela Frenquelli, Simone Cenci, Magda Marcatti, Roberto Sitia, Giovanni Tonon, Clara Camaschella   +8 more
doaj   +1 more source

Effective response with bortezomib retreatment in relapsed multiple myeloma

Swiss Medical Weekly, 2012
Previous studies have shown that retreatment of relapsed/refractory multiple myeloma (MM) with a second course of bortezomib therapy could be effective in heavily pre-treated patients.
Christian Taverna, Jérôme Voegeli, Andreas Trojan, Robert A Olie, Albert von Rohr   +4 more
doaj   +1 more source

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Haematologica, 2014
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules.
María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo   +14 more
doaj   +1 more source

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

Haematologica, 2020
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard ...
Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd Alonzo, John Choi, Brian Fisher, Robert Gerbing, Betsy Hirsch, Terzah Horton, Samir Kahwash, John Levine, Michael Loken, Lisa Brodersen, Jessica Pollard, Susana Raimondi, Edward Anders Kolb, Alan Gamis   +16 more
doaj   +1 more source

Bortezomib-induced skin eruption [PDF]

, 2008
Bortezomib (Velcad) is a proteasome inhibitor recently developed and mainly used for the treatment of multiple myeloma. Bortezomib represents a novel class of drugs functioning as proteasome inhibitors. Skin complications of bortezomib treatment are very
Favet, L, Sanchez-Politta, S., Piguet, Vincent, Kerl, K, Dietrich, Pierre-Yves, Piguet, V, Kerl, K., Dietrich, P Y, Sanchez-Politta, S, Favet, Laurence   +9 more
core   +1 more source

Investigation of the intrinsic mechanism of drug resistance in multiple myeloma [PDF]

, 2011
The focus of this thesis was to evaluate the mechanisms whereby myeloma cells develop intrinsic resistance with a focus on resistance in the context of bortezomib treatment.
Ooi, Melissa
core   +1 more source

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

Translational Oncology, 2017
Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity
Barbara Muz, Feda Azab, Pilar de la Puente, Yosef Landesman, Abdel Kareem Azab   +4 more
doaj   +1 more source